N-Ethylpentylone (β-keto-ethylbenzodioxolylpentanamine, βk-ethyl-K, βk-EBDP, ephylone) is a substituted cathinone and stimulant drug which was developed in the 1960s.[2][3]
It has been reported as a novel designer drug in several countries including the United Kingdom,[4] South Africa,[5] New Zealand,[6] the United States,[7] and Australia.[8]
In 2018, N-ethylpentylone was the most common drug of the cathinone class to be identified in Drug Enforcement Administration seizures.[9]
^GB 1085135, "Substituted phenyl-α-amino ketones", published 1969, assigned to Boehringer Sohn Ingelheim
^Wood MR, Bernal I, Lalancette RA (October 2017). "The hydrochloride hydrates of pentylone and dibutylone and the hydrochloride salt of ephylone: the structures of three novel designer cathinones". Structural Chemistry. 28 (5): 1369–1376. doi:10.1007/s11224-017-0951-x. ISSN1040-0400. S2CID102424824.
^Blanco G, Vidler D, Roper C, Wood DM, Dargan PI, Keating L, et al. (December 2021). "Acute toxicity from the synthetic cathinone N-ethylpentylone (ephylone) in the United Kingdom". Clinical Toxicology. 59 (12): 1270–1273. doi:10.1080/15563650.2021.1909730. PMID33855924. S2CID233242607.